Project Grant K08AI190124
Award Date 9/2/25
Completion Date 8/31/28
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- This federal Project Grant award of $895,538 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will fund research to discover all-oral sterilizing drug regimens, either made of FDA-approved agents or integrating novel preclinical and clinical candidates, to shorten treatment duration for patients with Mycobacterium abscessus pulmonary disease (MAB-PD). The research aims to identify...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- This Project Grant award of $2,944,529 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand resistance and tolerance to the tuberculosis (TB) drugs pretomanid (PA) and delamanid (DLM) in Mycobacterium tuberculosis (MTB). The goal is to apply innovative genome-wide screens to identify the MTB genes that determine PA/DLM potency, analyze the key resistance determinant...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on integrating point-of-care urine isoniazid testing into routine tuberculosis (TB) care in India. The research aims to facilitate early and accurate identification of TB patients who are at risk of poor outcomes, including death and disease recurrence, due to...
- This $415,978 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to identify novel boron-based inhibitors of mycobacterial class II aminoacyl-tRNA synthetases. The grant supports research at the University of Central Florida, in collaboration with AN2Therapeutics (formerly Anacor Pharmaceuticals), to develop new boron-containing antibiotics effective against Mycobacterium tuberculosis (MTB). The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research at Yale University to develop an in vitro culture system that can be used to screen for small molecule inhibitors of drug-tolerant Mycobacterium tuberculosis (MTB) bacteria. The key objectives are to: 1) identify the subcellular environment and carbon source associated with drug-tolerant MTB, and 2) design in vitro...